What are the OLYMPIA trials? OLYMPIA Clinical Trial Program Media Factsheet

OLYMPIA is a clinical trial program for patients with prurigo nodularis, designed to evaluate Nemluvio® (nemolizumab) for its potential to improve patient outcomes in clinical trials. The program includes two randomized, controlled trials: OLYMPIA 1 and OLYMPIA 2.

OLYMPIA 1 and OLYMPIA 2 are Phase 3, randomized, controlled trials investigating the efficacy and safety of Nemluvio in adults with prurigo nodularis. The trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH).

OLYMPIA 1

OLYMPIA 1 was a double-blind, placebo-controlled trial that enrolled 280 patients with prurigo nodularis. The trial compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 weeks. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 2

OLYMPIA 2 was a double-blind, placebo-controlled trial that enrolled 260 patients with prurigo nodularis. The trial compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 24 weeks. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA Clinical Trial Program

The OLYMPIA Clinical Trial Program is a comprehensive research initiative that includes the OLYMPIA 1 and OLYMPIA 2 trials. The program is designed to evaluate the efficacy and safety of Nemluvio in adults with prurigo nodularis and to advance the understanding of this chronic and debilitating neuroimmune skin disease. The OLYMPIA trials have provided valuable insights into the treatment of prurigo nodularis and have helped to improve patient outcomes.

The burden of prurigo nodularis

Prurigo nodularis is a chronic and debilitating neuroimmune skin disease characterized by the presence of intense itch and skin lesions. It is a serious condition that negatively impacts quality of life and can lead to a vicious cycle of scratching and itching. The disease is caused by complex interactions between the skin, nerve and immune cells, and can lead to anxiety and depression. The disease is underrecognized and underdiagnosed, and there are limited studies investigating its prevalence.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 and 24 weeks, respectively. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 and 24 weeks, respectively. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 and 24 weeks, respectively. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 and 24 weeks, respectively. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 and 24 weeks, respectively. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 and 24 weeks, respectively. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 and 24 weeks, respectively. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 and 24 weeks, respectively. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 and 24 weeks, respectively. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvio at two dosages (30 mg and 60 mg) with placebo for 16 and 24 weeks, respectively. The primary endpoint was the proportion of patients achieving at least 50% improvement in Investigator’s Global Assessment (IGA) at Week 16. Nemluvio met all primary and key secondary endpoints at Week 16.

OLYMPIA 1 and OLYMPIA 2 trials

The OLYMPIA 1 and OLYMPIA 2 trials were designed to address gaps identified in previous studies and were conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NIMH), and the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The trials compared Nemluvo